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Aims To investigate the efﬁcacy and safety of a cardiac resynchronization therapy with cardioverter–deﬁbrillator (CRT-D)
device with simpliﬁed ventricular tachycardia management in patients with non-ischaemic heart failure (HF) and
primary prevention implantable cardioverter deﬁbrillator (ICD) indication.
Methods
and results
Prospective, controlled, parallel, multicentre, non-randomized study enrolling 324 primary prevention non-ischaemic
HF patients implanted with CRT-D devices from 2004 to 2007: Protect group, 164 patients implanted with a Med-
tronic Insync III Protect device and Control group, 160 patients utilizing other Medtronic CRT-D devices.
Efﬁcacy was assessed by computing appropriate and inappropriate detections and therapies during follow-up; safety
compared hospitalizations and syncopal events between groups. Ninety per cent of both ventricular and supraventri-
cular tachyarrhythmias terminated within the 13–29 beat detection interval with the Protect algorithm. The Protect
group showed a signiﬁcantly better event-free survival to ﬁrst delivered therapy for total (P ¼ 0.0001), appropriately
treated (P ¼ 0.002), and inappropriately treated episodes (P ¼ 0.017). The total number of delivered shocks was sig-
niﬁcantly lower in the Protect group (22 vs. 59, P , 0.0001). In the Protect group, a signiﬁcantly reduced HF hospital-
ization (hazard ratio 0.38, 95% CI 0.15–0.98, P ¼ 0.044) was observed without any increase of syncope or death.
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doi:10.1093/eurheartj/ehp247Conclusion A simpliﬁed CRT-D device with ﬁxed long detection reduced overall ICD therapy burden and HF hospitalizations
without entailing any additional adverse events in primary prevention non-ischaemic HF patients.
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Introduction
Cardiac resynchronization therapy with cardioverter–deﬁbrillator
(CRT-D) back-up is indicated to reduce morbidity and mortality
in optimally treated heart failure (HF) patients, with reduced ejec-
tion fraction and wide QRS.
1,2
Increased interest is aimed at optimizing implantable cardiover-
ter deﬁbrillator (ICD) and CRT-D, by reducing shock burden
without jeopardizing the efﬁcacy of interventions, while, on the
other hand, rendering these sophisticated devices more readily
available by reducing device costs. Another issue hampering
CRT-D diffusion may relate to the correct programming process
which usually requires the collaborative expertise of physicians
as well as engineers.
From studies evaluating ‘shockless’ therapy delivered through
anti-tachycardia pacing (ATP),
3–5 three aspects have emerged
characterizing the arrhythmic proﬁle of patients with non-
ischaemic HF and primary prevention indication for an ICD. Com-
pared with other HF patient sub-groups, these patients generally
present a lower incidence of ventricular tachyarrhythmias (VA),
5
a great proportion of VA in this population have a short cycle
length (usually ranging from 240 to 320 ms) and these tend to
be self-terminating.
4,5
These notions found the rationale behind developing a CRT
device presenting a full-featured biventricular pacing capabilities
with ICD full-shock programmability and ‘easy-to-use ﬁxed ATP
programming’ like the Medtronic InSync III Protect CRT-D device.
Such a device may potentially offer all the advantages of biventricular
stimulation and protection from sudden cardiac death, while allow-
ing a cost-effective and wide diffusion of ICD technology.
The objective of the present study was to compare two different
approaches in non-ischaemic, primary prevention patients treated
with CRT-D, in terms of efﬁcacy and safety:
(i) standard CRT-D ‘full-featured device’ with a standard short 12/
16 number of intervals to detect (NID) for VA detection and
treatment;
(ii) full-featured CRT pacing device combined with simpliﬁed,
‘easy-to-use’ ICD features (Medtronic InSync III Protect) with
ﬁxed, long detection intervals (30/40 NID) with one ﬁxed
88% ATP burst in fast ventricular tachycardia (FVT) window,
‘monitor only’ VT window (32 beats detection), and full
shock capability.
Methods
Study design
RELEVANT is a prospective, controlled, parallel, multicentre, non-
randomized study comparing a long VT/VF detection and simpliﬁed
ICD programmability vs. standard tailored ICD programming in
patients with non-ischaemic cardiomyopathy and primary prevention
ICD indication.
Patient selection, device programming,
and follow-up
Patients were prospectively enrolled from 24 Italian Cardiological
Centers from March 2004 to April 2007. Each patient provided
written informed consent approved by each Hospital Ethical Commit-
tee. Eligible patients had non-ischaemic cardiomyopathy (deﬁned as no
previous history of myocardial infarction or ischaemia and no signiﬁ-
cant lesion at coronary angiography), presented a class I–IIa indication
for CRT, and no previous history of VA.
1,2 Enrolled patients were
implanted either with the Medtronic InSync III Protect device
(Protect group) or with other ‘conventional’ Medtronic CRT-D full-
featured models (InSync III Marquis, InSync Maximo, InSync Sentry,
Medtronic Inc., Minneapolis, MN, USA) (Control group); the former
device, being a full-featured CRT pace-maker with basic ICD
back-up, was sold in Europe at a price roughly 30–40% lower than
other conventional ‘Medtronic CRT-D devices’.
Device programming for each study group is detailed in Table 1. The
device programming for the different detection windows differed
mainly for two points: (i) NID was much longer in the Protect arm
(30/40) compared with the Control group (12/16); (ii) a monitor
only window for VT was ﬁxed in the Protect group and highly rec-
ommended in the Control group. In the Protect group, data on VA
of 12/16 cycle length could also be retrieved, thus allowing to assess
the overall ‘hypothetical detection’ of VA in the Protect arm if a
short NID window would have been utilized.
Before device implantation, all patients underwent clinical evalu-
ation, 12-lead electrocardiogram recording, and estimation of NYHA
functional class. Furthermore, echocardiographic examination was per-
formed at baseline and every 6 months and included: left ventricular
end-diastolic diameter and volume, end-systolic diameter and
volume, left ventricular ejection fraction (LVEF), and grading of mitral
valve regurgitation (from 0 to 4). Pharmacological treatment was main-
tained stable throughout the follow-up as much as possible, especially
with regard to anti-arrhythmic drugs.
Rhythm classiﬁcation
All the devices provide extensive retrievable diagnostic data, including
storage of date, time, tachycardia cycle length, ICD therapies, atrial and
ventricular electrograms at episode onset, detection, before and after
therapy delivery, and termination. Spontaneous arrhythmic episodes
detected by the device were validated by two-blinded expert electro-
physiologists. A third electrophysiologist was involved in episode
review when no consensus in episode classiﬁcation had been
reached. Analysed episodes were classiﬁed as VA, atrial ﬁbrillation/
tachyarrhythmias (AF/AT), or other events (T-wave oversensing or
noise), according to established criteria.
3 Appropriately detected/
treated episodes included VA detected/treated by the device that
was conﬁrmed to be ventricular in origin by the two experts.
Biventricular deﬁbrillator with ﬁxed long detection intervals 2759Inappropriately detected/treated episodes included AF/AT, T-wave
oversensing, or electromagnetic interference.
Episodes overwritten on device memory in case of arrhythmic
storm (that then could not be surely evaluated) were excluded from
the analysis.
Any episodes that terminated before delivery of device therapy
(either shock or ATP), or terminating spontaneously in a monitor
zone, were classiﬁed as spontaneously terminating. A therapy was
deﬁned as successful when normal rhythm was restored within ﬁve
beats after therapy delivery.
Assessment of adverse events
Cardiac events were considered syncope, cardiovascular hospitaliz-
ations, and deaths during follow-up. These events were computed
and reviewed by an independent data and safety monitoring board
composed of non-participating physicians. Syncope was deﬁned as a
transitory, complete loss of consciousness with loss of postural tone.
Acceleration was deﬁned as  10% cycle length reduction after
therapy.
3 Hospitalizations and deaths were classiﬁed as cardiac (HF
or sudden), non-cardiac, or unknown according to Epstein et al.
6
Patients undergoing left ventricle assist device or urgent heart trans-
plant were classiﬁed as HF deaths.
Statistics
Descriptive statistics were reported as mean and standard deviation
for normally distributed continuous variables, or median with 25th–
75th inter-quartile range in the case of skewed distribution. Absolute
and relative frequencies were reported for categorical variables. Com-
parisons of continuous variables were performed by two-tailed Stu-
dent’s t-test for normally distributed variables. Comparisons of
categorical variables were performed by means of the Fisher exact
test for extreme proportions or Chi-square otherwise.
The incidence rate ratio (IRR) of events between groups was calcu-
lated applying a Poisson regression analysis using generalized estimating
equation (GEE) methodology, considering the within-patient corre-
lation as independent. The number of events per patient was the
observed outcome and the follow-up period was included in the
model as offset.
Freedom from the ﬁrst delivered ICD intervention (ATP and/or
shock), also divided according to ﬁrst appropriate or inappropriate
interventions, was analysed by means of the Kaplan–Meier method
and differences were evaluated by performing log-rank test. A Cox
regression was performed to estimate the hazard ratio (HR) of ICD
intervention, comparing observed groups.
For statistical analysis, SPSS 12.0 software (SPSS Inc., Chicago, IL,
USA) and StataSE 9 (StataCorp, TX, USA) were used. A two-sided
P-value , 0.05 was considered statistically signiﬁcant.
Results
Three hundred and twenty-four patients with non-ischaemic HF
and primary prevention ICD indication were implanted with
CRT-D devices between March 2004 and September 2007: 164
patients were implanted with Medtronic Insync III Protect
devices (Protect group, NID 30/40); the other 160 patients were
implanted with ‘conventional’ Medtronic CRT-D models (InSync
III Marquis, InSync Maximo, InSync Sentry, Medtronic Inc., Minnea-
polis, MN, USA) (Control group, NID 12/16).
No signiﬁcant differences in baseline demographic and clinical
variables (Table 2) or in mean follow-up (mean 14 months) were
detected between the two groups. Also, baseline echocardio-
graphic parameters as well as medical therapy were similar
between the groups. Medications were stable throughout the
follow-up without signiﬁcant changes within the same group and
between the two study groups.
Table 1 details the differences in programmed tachycardia detec-
tion and therapy between the two groups.
Analysis of recorded episodes
A total of 883 episodes (331 episodes in Protect and 552 in
Control group) were validated and considered for the analysis.
Distribution of all (appropriate and inappropriate) recorded epi-
sodes is presented in Figure 1.
...............................................................................................................................................................................
Table 1 Comparison of programmed device settings in the two study groups
Device programming Protect group (n 5 164) Control group (n 5 160)
VF detection window [ms] 120–330 120–330
VF NID 30/40 12/16
VF RNID 12/16 9/12
Maximum energy of VF therapies, average [Joules] (SD) 30 (0) 34.2 (1.8)
Charge time [s] 5.9 7.1
FVT detection window [ms] 240–330 240–330
FVT counter Via VF Via VF
First FVT therapy, type Burst 8 pulses at 88% CL Burst 8 pulses at 88% CL
Second to last FVT therapy, type, mean energy (SD) CV, 30 (0) CV, 34.2 (1.8)
VT detection window 330–360 330–360
VT NID 32 16
VT RNID 12 12
VT therapies monitor, n (%) 164 (100) 107 (67)
VF, ventricular ﬁbrillation; FVT, fast ventricular tachycardia; VT, ventricular tachycardia; CL, cycle length; NID, number of intervals detected; RNID, redetection number
of intervals.
M. Gasparini et al. 2760Appropriately detected ventricular tachyarrhythmias
In order to estimate if the arrhythmic burden in the two groups
was similar, detected VA were evaluated in the Protect group con-
sidering both actual programming (NID 30/40) and 12/16 NID
hypothetical programming, as utilized in the Control group. The
analysis obtained with an equivalent ‘short’ NID (12/16) pointed
out that the two groups presented very similar ‘true ventricular
arrhythmic burden’: utilizing an equal short NID, in fact, the
number of appropriately detected episodes would have been
311 in the Protect and was 310 in the Control groups (IRR ¼
0.96, 95% CI 0.82–1.12, P ¼ 0.592) (grey bars in Figure 2A and B).
Distribution of VA was comparable between groups: VF epi-
sodes were 12 in the Protect group and 6 in the Control group,
FVT 168 and 172, VT 131 and 132, respectively. However, pro-
longed NID used in the Protect group allowed to correctly identify
282/311 (91%) as VA episodes which self-terminated in the interval
between 13 and 29 beats.
More speciﬁcally in the Protect group, 8 out of 12 (66%) VF, and
153/168 (91%) FVT episodes terminated spontaneously within
29 beats, while 121/131 (92%) VT episodes self-terminated within
31 beats (black bars in Figure 2A). While within the Control
group (with FVT/VF detection at NID 12/16), most of these
...............................................................................................................................................................................
Table 2 Baseline characteristics
Protect group (n 5 164) Control group (n 5 160) P-value
Follow-up period (SD) 14.0 (10.4) 14.4 (8.5) 1.000
Male gender, n (%) 126 (76.8) 120 (75) 0.700
Age (SD) 64.2 (11.7) 64.2 (10.8) 0.989
Diabetes history, n (%) 32 (19.5) 25 (15.6) 0.372
NYHA class (SD) 2.67 (0.59) 2.66 (0.57) 0.947
Permanent AF, n (%) 29 (17.7) 23 (14.4) 0.703
QRS width (ms), (25th–75th) 163 (135–183) 160 (140–170) 0.081
LVEF (SD) 24.6 (5.9) 25.4 (5.3) 0.269
LVEDD (SD) 70 (9) 71 (13) 0.727
LVESD (SD) 58 (10) 58 (11) 0.950
LVEDV (SD) 232 (70) 246 (94) 0.275
LVESV (SD) 168 (58) 184 (76) 0.184
Mitral regurgitation, n (%) 105 (64) 108 (67.5) 0.696
ACE-inhibitors and/or ARB, n (%) 121 (74) 125 (78) 0.220
Beta-blockers, n (%) 131 (80) 117 (73) 0.120
Amiodarone, n (%) 40 (26) 49 (31) 0.216
Diuretics, n (%) 139 (85) 132 (83) 0.514
Digitalis, n (%) 57 (35) 51 (32) 0.510
NYHA, New York Heart Association; AF, atrial ﬁbrillation; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular
end-systolic diameter; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume.
Figure 1 Distribution and numbers of all detected episodes (appropriate and inappropriate) in the two study groups.
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arm with NID 30/40, the great majority (282/311 episodes, 91%)
of these episodes were not treated as these were self-terminating
ventricular arrhythmias.
Inappropriately detected episodes
The number of inappropriately detected episodes (AF/AT, T-wave
over-sensing or noise) differed signiﬁcantly between the two
groups, amounting to only 20 in Protect and 242 episodes in
Control groups (IRR ¼ 0.08, 95% CI 0.05–0.12, P , 0.0001)
(Figures 1 and 3). In both groups, less than 10% of inappropriate
episodes were due to noise or oversensing, while most inappropri-
ately recorded episodes were determined by supraventricular
tachyarrhythmias (AT/AF); speciﬁcally 18/20 (90% of inappropriate
detections) episodes for Protect group and 225/242 episodes
(93%) for Control group.
Figure 2 Distribution of all appropriately detected episodes in the Protect (A) and in the Control (B) groups are presented. The distribution
is distinguished according short to 12/16 NID setting (grey bars) and long 30/40 NID (black bars).
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A total of 325 treated episodes were recorded in 48 patients: 12
patients in Protect group and 36 patients in Control group.
Overall, event-free survival to ﬁrst delivered therapy (ATP or
shock, appropriate and inappropriate) was dramatically lower in
the Protect arm (log-rank ¼ 15.02, P , 0.0001 for all therapies).
A signiﬁcantly lower number of interventions were observed in
Protect compared with Control, respectively, 36 episodes vs.
289 episodes (IRR ¼ 0.12, 95% CI 0.08–0.17, P , 0.0001)
(Figure 3); also, few shocks occurred in the Protect group
(Protect 22 shocks vs. 59 shocks for Control, IRR ¼ 0.36, 95%
CI 0.22–0.58, P , 0.0001) (Figure 3).
Appropriately treated VA episodes
Appropriately treated VA amounted to 267. Appropriately treated
episodes were signiﬁcantly lower for the Protect arm (only 26 epi-
sodes in nine patients) compared with Control (241 episodes in 26
patients, IRR ¼ 0.10, 95% CI 0.07–0.15, P , 0.0001) (Figure 3).
Considering appropriate shock therapy, a trend towards a signiﬁ-
cantly lower number of shocks was observed in the Protect arm
(Protect 17 episodes vs. Control 29, IRR ¼ 0.56, 95% CI 0.31–
1.02, P ¼ 0.057) (Figure 3).
Kaplan–Meier analysis (Figure 4A) further supported these ﬁnd-
ings by showing a signiﬁcantly superior event-free survival to ﬁrst
delivered therapy in the Protect group (log-rank ¼ 9.67, P ¼
0.002).
Inappropriately treated episodes
Due to the longer NID utilized in the Protect arm, the number of
inappropriately treated episodes were remarkably lower for the
Protect group, numbering only 10 events compared with 48
events for the Control group (IRR ¼ 0.20, 95% CI 0.10–0.39,
P , 0.0001) (Figure 3). Likewise, Protect group presented a
signiﬁcantly lower number of shocks compared with Control
group (5 and 30 shocks, respectively, IRR ¼ 0.16, 95% CI
0.06–0.41, P , 0.0001) (Figure 3). Kaplan–Meier analysis (Figure 4B)
conﬁrmed signiﬁcantly superior event-free survival to ﬁrst
inappropriate therapy (log-rank ¼ 6.26, P ¼ 0.012) in Protect arm.
Outcome data
Data concerning NYHA class and EF at 6 months were not avail-
able in 18 and 33 patients, respectively, while 28 patients were
lost to follow-up. All other outcome variables were available in
both groups. No signiﬁcant differences in clinical outcomes were
observed between the two groups at 6 months: mean NYHA
class was 1.96+0.55 in Protect group vs. 2.03+0.59 in
Control group, P ¼ 0.276; mean LVEF (%) was 29.1+10.9 in
Protect group vs. 27.5+8.1 in Control group (P ¼ 0.316).
During follow-up, two syncope were observed in Protect group
(one due to prolonged detection on a FVT and one due to FVT
acceleration after ATP), while three episodes occurred in
Control group (all due to VT acceleration after ATP) (P ¼
0.465). Freedom from the ﬁrst HF hospitalization was signiﬁcantly
better in Protect than in Control patients (log-rank ¼ 4.31, P ¼
0.038) (Figure 5) and there was a 60% risk reduction of total HF
hospitalizations for the Protect group (HR ¼ 0.38, 95% CI 0.15–
0.98, P ¼ 0.044).
At the end of the follow-up period, 6 deaths were observed: in
both Protect and Control groups three patients died (P ¼ 1.000),
with a similar incidence of 1.8 per 100 patient years and 1.9 per
100 patient years, respectively.
Discussion
This study investigated, for the ﬁrst time, the efﬁcacy and safety of a
simpliﬁed ICD strategy in a multicentre, prospective, comparative,
Figure 3 Poisson regression estimates (GEE adjusted) of incidence rate ratio (IRR) values of ICD interventions between Protect and Control
groups.
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primary prevention indication treated with CRT-D. The potential
advantages of an ‘empiric’ programming with longer NID in the
FVT/VF windows have already been demonstrated in patients
with LV dysfunction and ICD indication.
7,8 However, the present
study differs from previous ones in several aspects. Compared
with the present study, the EMPIRIC study
7 tested detection set
at NID 18/24 and not 30/40. Also, in EMPIRIC, only half of the
patients enrolled were implanted in primary prevention and
most patients presented ischaemic aetiology. The PREPARE
study
8 tested long detection algorithm in patients implanted with
conventional and biventricular ICD in primary prevention against
a retrospective control cohort gathered from previous EMPIRIC
and MIRACLE-ICD studies.
9 Moreover, as in EMPIRIC, most
patients included presented ischaemic aetiology. Very different
from these previous studies,
7,8 the present one considered a
speciﬁc HF patient population treated with CRT-D and evaluated
a strategy, mainly characterized by a long 30/40 NID FVT detection
window, compared with a Control group with conventional ‘tai-
lored’ ICD programming. The study demonstrated that this strat-
egy with long detection reduced the number of overall
interventions (appropriate and inappropriate), without undermin-
ing effective ICD therapy. Moreover, patients treated with this
algorithm did not exhibit increased adverse effects (such as
increased syncopal episodes) but, on the contrary, HF hospitaliz-
ation was found to be signiﬁcantly lower compared with Control.
Figure 4 Kaplan–Meier analysis of event-free survival to ﬁrst delivered therapy for appropriate (A) or inappropriate episodes (B).
M. Gasparini et al. 2764Self-terminating ventricular
tachyarrhythmias in primary prevention
non-ischaemic heart failure patients
The comparison of the two groups with different detection set-
tings allowed to provide some fundamental information on the
natural history of VA in this patient sub-group.
These data have been obtained not only by an inter-group com-
parison, but also through an intra-group analysis inside the Protect
group by discriminating between the shorter FVT episodes, which
would have been hypothetically detected within NID 12/16, and
the more prolonged episodes that reached 30/40 NID. This dis-
tinction allowed to conﬁrm the very similar VA proﬁle between
the two groups, thus emphasizing that a dramatic reduction of
the incidence of detected and treated VA can be obtained by
setting a long 30/40 NID.
In fact, the great majority of true VT and FVT (more than 90%),
which in the Control arm entered the treatment window, were
found to self-terminate within 30 beats in the Protect arm, and,
more importantly, in the Protect group, only one-third of VF actu-
ally reached 30 beats, thus necessitating shock therapy.
The concept that long detection offers the possibility for VA to
terminate spontaneously is not a novel one and has been pre-
viously raised, mainly in patients treated with single or dual
chamber ICDs.
4,7,8,10 The simple additional detection delay of
mean 3.3 s present during charge in the shock therapy group in
PainFREE Rx II
4 allowed to observe that a high proportion of
FVT (34%) would terminate spontaneously in the 3 s time interval
following 18/24 NID. In the present study, the different NID
windows determined a mean detection time of 3.7 s for Control
group, and 9.3 s for Protect group before any therapy was deliv-
ered; this almost 6 s delay may explain the dramatic reduction of
arrhythmias really necessitating treatment. More recent studies
performed on large numbers of heterogeneous patients with LV
dysfunction and ICD indication observed that standardized ICD
programming, that included long detection, effectively reduced
shock-related morbidity.
7,8
The present study found that appropriate ICD interventions
were signiﬁcantly lower for the Protect group (P , 0.0001), and
happened to be virtually one-tenth of the number of interventions
in the Control group. This suggests vice versa that almost 90% of
the appropriate interventions observed in the Control group were
probably applied on VA which may have otherwise self-terminated
with a longer NID window.
The importance of self-terminating
supraventricular tachyarrhythmias in
primary prevention non-ischaemic heart
failure patients
One of the most remarkable features derived from the comparison
of the two ICD strategies is the dramatically lower number of inap-
propriate detections in the Protect arm (Protect only 20 episodes
vs. 242 episodes in the Control arm, P ,0.0001). The long NID
strategy may have substantially contributed to effectively abolish
inappropriate detections in this patient population. Similar to
what has been already reported, most inappropriate interventions
are determined by high-rate AT/AF,
4,11,12 especially in HF patients
with history of AF, representing 20–40% of all inappropriate thera-
pies. In our series, the comparison between the different NID
allowed to assume that around 90% of AT/AF were found to
resume in a 12–30 beat interval. Even this information on atrial
arrhythmias, to our knowledge, has never been reported before
and may play an important role in optimizing ICD detection and
therapy in these patients. In fact, the number of inappropriate
interventions was signiﬁcantly lower for the Protect group both
Figure 5 Kaplan–Meier analysis of event-free survival to ﬁrst heart failure hospitalizations.
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sodes in Control group, P ¼ 0.0001) and shocks (5 episodes in
the Protect group and 30 episodes for Control, P , 0.0001).
Taken together, the evidence presented herein shows that AT/
AF in this particular population tend to terminate spontaneously,
further reinforcing the concept that setting long NID and ‘VT
monitor only zone’ is advisable.
13
Reducing the burden of ICD interventions
using long detection intervals
The present study found that prolonged 30/40 detection signiﬁ-
cantly reduced the burden of ICD interventions without increasing
the incidence of syncope: in this regard, the observed incidence of
syncope in the Protect arm was low and comparable with the
Control group (1.2 vs. 1.9%). These incidences are in line with pre-
vious observations derived from ICD studies
3,4 and conﬁrm the
safety of long detection programming.
7,8 The overall burden of
shocks (appropriate and inappropriate), evaluated through
Poisson regression analysis (Figure 3), was signiﬁcantly lower for
the Protect group (,0.0001). More speciﬁcally, in the Protect
group the proportion of inappropriate shocks was signiﬁcantly
lower (P , 0.0001) compared with the Control group; concerning
appropriate shocks a trend towards a lower proportion of these
events was also found (P ¼ 0.057).
It is well known that direct current (DC) shock may have a pro-
found negative impact on quality of life,
14 morbidity, and even sur-
vival.
11,15,16 This is particularly true in patients with refractory HF
implanted with CRT-D, in whom both appropriate and inappropri-
ate shocks may increase morbidity and mortality in different ways,
including myocardial depression,
17,18 pro-arrhythmic effect of DC
shock,
15,16 thromboembolic complications after DC shock,
19 and
increased stress-related sympathetic tone which is
pro-arrhythmogenic and pro-thrombotic.
20
In the present study, as a result of the lower number of appro-
priate and inappropriate therapies delivered in the Protect arm, sig-
niﬁcantly lower HF hospitalizations were observed in this group,
suggesting that too much ICD therapy and interventions may be
detrimental in this patient sub-group. Of note, this intriguing
ﬁnding runs in line with the recent results of a sub-study of the
SCD-HeFT trial that identiﬁed ICD shocks (whether appropriate
or inappropriate) as independent predictors of death, particularly
HF death,
21 in HF patients treated with conventional ICD.
Clinical implications
The ﬁndings herein support the use of a simpliﬁed programming
(FVT with long detection and single burst ATP, monitor only VT
window) in a speciﬁc HF patient sub-group with non-ischaemic
HF aetiology, ventricular conduction delay, and primary prevention
indication for an ICD. In this patient sub-group, too sensitive anti-
tachycardia diagnostic and therapeutic settings may dramatically
increase ICD therapy burden and may, paradoxically, increase HF
hospitalizations. It would be reasonable to evaluate whether such
a simpliﬁed approach with long detection would be effective in
patients with ischaemic HF patients implanted for primary preven-
tion as these patients usually have a low incidence of ventricular
arrhythmic events.
22 The diffusion of such a strategy incorporated
in a simpliﬁed ICD device with ﬁxed programming to ischaemic
patients as well may entail a remarkable reduction of costs while
ensuring a wider access to ICD technology. Also, in light of the
present study ﬁndings, the possibility of programming even
longer NID may be evaluated in the future.
In the present study, the use of a simpliﬁed device for CRT-D,
with a lower price, was associated with favourable results and
this may have important implications in an economic perspective.
A series of cost-effectiveness studies
23,24 demonstrated that lower-
ing the cost of an ICD would improve the incremental cost-
effectiveness of device therapy. Focusing on CRT, a series of
studies have provided varying estimates of the cost-effectiveness
of CRT-P and CRT-D relative to medical treatment,
25 but the
incremental cost-effectiveness of CRT-P vs. CRT-D remains not
well deﬁned. A reduction in the incremental cost of CRT-D vs.
CRT-P, as obtained in our experience by simpler CRT-D
devices, may substantially improve the incremental cost-
effectiveness of CRT-D vs. CRT-P. The important 60% reduction
of HF hospitalization observed in the Protect group, combined
with an upfront cost reduction of CRT-D devices by roughly
30–40%, may determine an improvement in cost effectiveness
that could be the basis for promoting a more homogeneous
implementation of current guidelines on CRT-D, trying to over-
come current inequalities in the ‘real world’.
26,27
Study limitations
This is a prospective, multicentre, controlled, parallel study. The
major limitation is that treatment assignment was not randomized,
but it was centrally based with availability of the ﬁrst or second
type of device mainly determined on the basis of regional device
allocation policy. This centralized treatment assignment modality
was even dictated by difﬁculties to obtain a full echonomical
support for a randomized study. It is worthwhile to consider,
however, that the participating Centers were all regional referral
Centers for device implant and that the experience in CRT implan-
tation between Centers enrolling Protect vs. Control patients was
found to be equivalent, both in terms of volume, success rate of
implants, as well as mean number of years of experience in CRT
device implant. For the above-mentioned reasons, no major bias
was observed in the study, nonetheless the non-randomized
nature of the study could not permit to exclude the presence of
minor selection biases.
Data on quality of life were obtained only in a minority of the
study population, and no statistical evaluation was therefore
possible.
Finally, the comparison with the Protect (30/40 NID) group was
performed against Control group utilizing 12/16 and not 18/24
NID; though this latter NID has recently shown to be effective
and safe in ICD recipients,
7,8 the present study was started at a
time when NID was conventionally programmed at 12/16.
Conclusions
In patients with non-ischaemic HF and conventional primary pre-
vention indication for a CRT-D, a simpliﬁed CRT-D with full
shock capability, and pre-set long detection window (30/40 NID)
determined a dramatic reduction of ICD interventions without
M. Gasparini et al. 2766either jeopardizing ICD therapy capabilities or entailing increased
morbidity. Further studies conﬁrming that the effectiveness of
this simpliﬁed and cheaper strategy in HF primary prevention
ischaemic patients could allow a wider diffusion and availability of
this life-saving device therapy.
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